Innovita Biological Technology Co. Ltd. A (688253) — Cash Flow-to-Debt Ratio

Latest as of December 2025: 0.86x

Innovita Biological Technology Co. Ltd. A (688253) has a Cash Flow-to-Debt Ratio of 0.86x as of December 2025, meaning its operating cash flow of CN¥193.13 Million could theoretically repay 1% of its total liabilities (CN¥223.32 Million) in one year. See Innovita Biological Technology Co. Ltd. (688253) free cash flow to measure how efficiently the company converts operating cash flow to free cash.

CF-to-Debt Ratio

0.86x
Operating CF / Total Liabilities

Operating Cash Flow

CN¥193.13 Million
CNY

Total Liabilities

CN¥223.32 Million
CNY

Data as of

Dec 2025
Most recent filing

Innovita Biological Technology Co. Ltd. A Cash Flow-to-Debt Ratio (2020–2025)

Historical debt coverage capacity for Innovita Biological Technology Co. Ltd. A across 6 annual periods. Also explore Innovita Biological Technology Co. Ltd. annual equity growth to track the company's year-over-year net asset growth rate.

Annual Cash Flow-to-Debt Ratio for Innovita Biological Technology Co. Ltd. A (2020–2025)

Year-by-year debt coverage analysis for Innovita Biological Technology Co. Ltd. A. For market capitalisation and broader financial context, see 688253 market cap.

Year CF-to-Debt Ratio Operating CF (CNY) Total Liabilities YoY Change
2025 0.86x CN¥193.13 Million CN¥223.32 Million ▼ -38.0%
2024 1.39x CN¥305.46 Million CN¥219.07 Million ▲ +20.0%
2023 1.16x CN¥259.85 Million CN¥223.65 Million ▲ +132.7%
2022 0.50x CN¥126.43 Million CN¥253.24 Million ▼ -72.0%
2021 1.78x CN¥106.27 Million CN¥59.70 Million ▼ -68.3%
2020 5.61x CN¥639.82 Million CN¥114.08 Million
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.